Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
An organophosphate insecticide that inhibits monoamine oxidase and acetylcholinesterase. It has been shown to be genotoxic.
Transplantation of an individual's own tissue from one site to another site.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Surgical insertion of cylindric hydraulic devices for the treatment of organic ERECTILE DYSFUNCTION.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Progenitor cells from which all blood cells derive.
Centers for collecting, characterizing and storing human blood.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
The return of a sign, symptom, or disease after a remission.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
The transference of a part of or an entire liver from one human or animal to another.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Immunological rejection of leukemia cells following bone marrow transplantation.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
Elements of limited time intervals, contributing to particular results or situations.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
Disorders of the blood and blood forming tissues.
Cells derived from the BLASTOCYST INNER CELL MASS which forms before implantation in the uterine wall. They retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
The transference of a kidney from one human or animal to another.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A multisystemic disorder characterized by a sensorimotor polyneuropathy (POLYNEUROPATHIES), organomegaly, endocrinopathy, monoclonal gammopathy, and pigmentary skin changes. Other clinical features which may be present include EDEMA; CACHEXIA; microangiopathic glomerulopathy; pulmonary hypertension (HYPERTENSION, PULMONARY); cutaneous necrosis; THROMBOCYTOSIS; and POLYCYTHEMIA. This disorder is frequently associated with osteosclerotic myeloma. (From Adams et al., Principles of Neurology, 6th ed, p1335; Rev Med Interne 1997;18(7):553-62)
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
A cylindrical column of tissue that lies within the vertebral canal. It is composed of WHITE MATTER and GRAY MATTER.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Cells with high proliferative and self renewal capacities derived from adults.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A strain of non-obese diabetic mice developed in Japan that has been widely studied as a model for T-cell-dependent autoimmune insulin-dependent diabetes mellitus in which insulitis is a major histopathologic feature, and in which genetic susceptibility is strongly MHC-linked.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A general term for various neoplastic diseases of the lymphoid tissue.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
Cells that can give rise to cells of the three different GERM LAYERS.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
The transference of a heart from one human or animal to another.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Persons or animals having at least one parent in common. (American College Dictionary, 3d ed)
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.

Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. (1/440)

BACKGROUND AND PURPOSE: Human umbilical cord blood cells (HUCBC) are rich in stem and progenitor cells. In this study we tested whether intravenously infused HUCBC enter brain, survive, differentiate, and improve neurological functional recovery after stroke in rats. In addition, we tested whether ischemic brain tissue extract selectively induces chemotaxis of HUCBC in vitro. METHODS: Adult male Wistar rats were subjected to transient (2-hour) middle cerebral artery occlusion (MCAO). Experimental groups were as follows: group 1, MCAO alone (n=5); group 2, 3x10(6) HUCBC injected into tail vein at 24 hours after MCAO (n=6) (animals of groups 1 and 2 were killed at 14 days after MCAO); group 3, MCAO alone (n=5); group 4, MCAO injected with PBS at 1 day after stroke (n=8); and group 5, 3x10(6) HUCBC injected into tail vein at 7 days after MCAO (n=5). Rats of groups 3, 4, and 5 were killed at 35 days after MCAO. Behavioral tests (rotarod and Modified Neurological Severity Score [mNSS]) were performed. Immunohistochemical staining was used to identify cells derived from HUCBC. Chemotactic activity of ischemia brain tissue extracts toward HUCBC at different time points was evaluated in vitro. RESULTS: Treatment at 24 hours after MCAO with HUCBC significantly improved functional recovery, as evidenced by the rotarod test and mNSS (P<0.05). Treatment at 7 days after MCAO with HUCBC significantly improved function only on the mNSS (P<0.05). Some HUCBC were reactive for the astrocyte marker glial fibrillary acidic protein and the neuronal markers NeuN and microtubule-associated protein 2. In vitro, significant HUCBC migration activity was present at 24 hours after MCAO (P<0.01) compared with normal brain tissue. CONCLUSIONS: Intravenously administered HUCBC enter brain, survive, migrate, and improve functional recovery after stroke. HUCBC transplantation may provide a cell source to treat stroke.  (+info)

Listeriosis in recipients of allogeneic blood and marrow transplantation: thirteen year review of disease characteristics, treatment outcomes and a new association with human cytomegalovirus infection. (2/440)

Listeriosis is uncommon in recipients of allogeneic blood, marrow and organ transplantation. Six patients with systemic Listeria monocytogenes infection during 1985-1997 at Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center are described. In two male and four female patients, the median duration from transplantation to isolation of L. monocytogenes was 62.5 (range 29 to 821) days. Among five allogeneic marrow transplant recipients, four (80%) received HLA antigen matched, T cell-depleted grafts from three unrelated and a single related donor. One patient underwent mismatched-related marrow graft transplant. Cord stem cell transplantation was performed in a single patient. Two required therapy for graft-versus-host disease (GVHD). The 13 year incidence of systemic Listeria infections was 0.47 percent. All six presented with fever (>39 degrees C), and L. monocytogenes bloodstream invasion. Mental status changes and meningioencephalitis were observed in two (33.3%). A concurrent primary opportunistic infection was present in five individuals (83.3%), and four (80%) were being treated for acute human cytomegalovirus (HCMV) viremia. Sixty-six percent responded to therapy and two died from unrelated, non-listeric causes. Systemic listeriosis was uncommon in our high-risk allogeneic blood and marrow transplantation population, and response to therapy with parenteral ampicillin and gentamicin was excellent. The association between primary HCMV reactivation and subsequent listeric infection emphasizes the significance of HCMV-related dysfunction in hosts' cellular immune responses, especially in the setting of allogeneic transplantation.  (+info)

Human herpesvirus-6 encephalitis after unrelated umbilical cord blood transplant in children. (3/440)

Three children developed human herpesvirus-6 (HHV-6), variant B encephalitis after unrelated umbilical cord blood transplant, in a single center. They developed clinical manifestations of encephalitis around day 17 post transplant. Impairment of consciousness, incoherent speech, episodic focal pruritus, motor weakness, convulsions and severe hyponatremia were features at presentation. Radiological investigation of brain ranged from unremarkable to extensive white matter and meningeal lesions. Diagnosis was established by the presence of HHV-6 DNA in cerebrospinal fluid (CSF). Retrospective analyses of plasma revealed the presence of viral DNAemia prior to the onset of disease in two subjects. Treatment with ganciclovir or foscarnet was given. Two subjects did not achieve engraftment and died of other transplant-related complications on day 38 and 56 post-transplant, respectively. One subject achieved disease-free survival for more than 1 year with a satisfactory neurological outcome. In conclusion, HHV-6 encephalitis is not uncommon among patients undergoing umbilical cord blood transplantation. It is worth conducting further studies on early diagnosis and optimal management of this potentially fatal disease.  (+info)

Successful treatment of relapsed blastic natural killer cell lymphoma with unrelated cord blood transplantation. (4/440)

The prognosis for blastic natural killer (NK) cell lymphoma is generally dismal. We report a patient who was successfully treated with unrelated cord blood transplantation (UCBT). A 15-year-old boy was diagnosed as having blastic NK cell lymphoma in the cervical lymph nodes. Autologous peripheral blood stem cell transplantation was performed on achieving a complete remission. However, the disease recurred in the bone marrow 6 months later. Chemotherapy induced a second remission and the patient received UCBT with a conditioning regimen consisting of total body irradiation, thiotepa and cyclophosphamide. Chronic GVHD of the lung occurred, but it was well controlled with steroids. At the time of writing, he remains in remission 18 months after UCBT with an excellent performance status. UCBT may be an option for patients with blastic NK cell lymphoma.  (+info)

Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. (5/440)

In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4(+) T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.  (+info)

A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation. (6/440)

An 11-month-old boy with acute lymphoblastic leukemia (ALL) underwent umbilical cord blood transplantation (CBT) from an unrelated donor after a first complete remission. Despite the prophylactic use of low molecular weight heparin, prostaglandin E1 and ursodeoxycholic acid, hepatic veno-occlusive disease (VOD) occurred on the 29th day after CBT. Furthermore, neither defibrotide nor antithrombin-III improved the hepatic coma and coagulopathy due to the hepatic VOD. On the 42nd day after CBT, he underwent living related liver transplantation (LRLT) with a left lateral segment graft from his father. He received tacrolimus for the prevention of rejection and graft-vs.-host disease (GVHD) and also received aggressive antifungal and antiviral prophylaxis. Although he showed signs of acute rejection on postoperative days 5 and 10, the postoperative course was uneventful in general. At present, 17 months after LRLT, the patient shows stable liver function and no signs of either GVHD or a relapse of ALL. In conclusion, LRLT can be seen as a feasible option for the treatment of a hepatic VOD after CBT, though aggressive prophylaxis for infection and the anticipation of acute rejection are of importance.  (+info)

"Saviour siblings". (7/440)

The Victorian Infertility Treatment Authority has given permission to allow tissue typing in combination with preimplantation genetic diagnosis. This is a new application of IVF. Not only will it allow parents to select an embryo free from serious genetic disease it will allow them to simultaneously select for a match so that the umbilical cord blood of the resulting baby can provide stem cells to treat an existing sibling who has a disease.  (+info)

Induction of graft-versus-host disease and a graft-versus-leukemia effect using ubenimex in a patient with infantile leukemia relapsing after an unrelated cord blood transplant. (8/440)

A 20-month-old boy with infantile leukemia was treated with total body irradiation, etoposide, cyclophosphamide and unrelated cord blood transplantation with a one-antigen mismatch. He relapsed on day 100 and achieved remission after ubenimex administration, and also developed chronic graft-versus-host disease of the skin. He remained in remission for 22 months with repeated courses of ubenimex. Ubenimex may be an alternative to donor lymphocyte transfusion and may be useful for the treatment of a patient who has relapsed after cord blood transplantation.  (+info)

Banking and Transplantation of Unrelated Donor Umbilical Cord Blood: Status of the National Heart, Lung, and Blood Institute-Sponsored ...
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer. Giving chemotherapy and total-body irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patients immune system from rejecting the donors stem cells. When the healthy stem cells from an unrelated donor, that do not exactly match the patients blood, are infused into the patient they may help the patients bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the bodys normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening ...
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer. Giving chemotherapy and total-body irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patients immune system from rejecting the donors stem cells. When the healthy stem cells from an unrelated donor, that do not exactly match the patients blood, are infused into the patient they may help the patients bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the bodys normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening ...
Double-Unit Cord Blood Transplantation Not Superior to Single-Unit in Reducing Risk of Transplant Failure in Children and Young Adults - From the Blood Journals, News, Written in Blood - ASH Clinical News
We describe outcomes of a large series of predominantly small and young children with IMDs belonging to the lysosomal and peroxisomal disorders who underwent transplantation with UCBT at a single center after uniform cytoreduction and were followed for 1 to 11 years (median, 4.6 years). Important variables improving OS significantly were better performance status (P , .001), higher infused CFUs (P = .02), and matched ethnicity between the CBU and the recipient (P = .05). The cumulative incidence (87.1% by day 42) and speed (median, day 22) of neutrophil engraftment was higher and faster than previously reported in large cohort studies.27,28,42 Most patients (97%) achieved and sustained full donor chimerism (, 90%) and normalized enzyme levels where measurable. This high level of donor chimerism is better than those reported in the literature after unrelated bone marrow transplantation. Although detailed, disease-specific outcomes are not fully described in this report; all surviving children ...
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide (CY), fludarabine phosphate (FLU), and total-body irradiation (TBI) works in treating patients with hematologic disease.. Giving chemotherapy, such as CY and FLU, and TBI before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patients immune system from rejecting the donors stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patients bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the bodys normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening.. ...
This study is currently recruiting participants. Verified June 2012 by Fred Hutchinson Cancer Research Center First Received on July 25, 2008. …
Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.
TY - JOUR. T1 - Retention of stemness and vasculogenic potential of human umbilical cord blood stem cells after repeated expansions on PES-nanofiber matrices. AU - Joseph, Matthew. AU - Das, Manjusri. AU - Kanji, Suman. AU - Lu, Jingwei. AU - Aggarwal, Reeva. AU - Chakroborty, Debanjan. AU - Sarkar, Chandrani. AU - Yu, Hongmei. AU - Mao, Hai Quan. AU - Basu, Sujit. AU - Pompili, Vincent J.. AU - Das, Hiranmoy. PY - 2014/10. Y1 - 2014/10. N2 - Despite recent advances in cardiovascular medicine, ischemic diseases remain a major cause of morbidity and mortality. Although stem cell-based therapies for the treatment of ischemic diseases show great promise, limited availability of biologically functional stem cells mired the application of stem cell-based therapies. Previously, we reported a PES-nanofiber based ex vivo stem cell expansion technology, which supports expansion of human umbilical cord blood (UCB)-derived CD133+/CD34+ progenitor cells ~225 fold. Herein, we show that using similar ...
In a new peer-reviewed article published by the Journal of Translational Medicine, scientists from Beike Biotechnology,Chinas leading stem cell research and regenerative medicine company, and Medistem, Inc.,reported positive safety data in 114 patients who were treated by doctors at Nanshan Affiliated Hospital of Guangdong Medical College (Shenzhen Nanshan Hospital) in Shenzhen using Beikes proprietary cord blood stem cell transplantation protocol.
We studied the effect of the inter-unit HLA match on outcomes of double UCB transplantation for acute leukemia and did not find an association between inter-unit HLA-mismatch and outcomes. Specifically, there were no differences in hematopoietic recovery, acute GvHD or survival, demonstrating that inter-unit HLA-match is not relevant when selecting UCB units for double UCB transplantation for acute leukemia. The only unit characteristic associated with neutrophil recovery was cell dose. Transplantations of UCB units with a combined infused TNC 4×107/kg or more was associated with faster neutrophil recovery, but infused TNC was not associated with survival or non-relapse mortality. There were no differences in engraftment of the dominant and non-dominant units based on inter-unit HLA match or unit TNC within the first month after transplantation. Our observations are not in keeping with a single report of early engraftment of the non-dominant UCB unit when the cell dose of the dominant unit was ...
Our goal is to increase the number of immature umbilical cord blood stem cells (UCBSCs) for hematopoietic transplantation. Towards this goal, our lab adapted a culture technique to grow immature CD133+ UCBSCs (CD133+ cells). Although CD133+ cells proliferate rapidly in culture, a minority self-renew and remain CD133+, while a majority differentiate and become CD133-. Therefore, new strategies to identify and grow immature UCBSCs are important. Since little is known about signally mechanisms regulating self-renewal and differentiation of UCBSCs, we sought insight from embryonic stem cell (ESC) literature to guide our studies. \r\nTo identify a population of UCBSCs that grow without differentiating, we focused on Oct-4, a transcription factor essential for self-renewal in ESCs that we previously reported expression in UCBSCs. During our studies, new challenges in the field arose. Two isomers of Oct-4 were discovered, Oct-4A and Oct-4B 3, in which only Oct-4A conferred the ability of ESCs to ...
This retrospective study aimed to assess the safety of patients with severe cerebral palsy (CP), who received allogeneic umbilical cord blood stem cells (UCBSCs) treatment from August 2009 to December 2012 in Guangdong Provincial Hospital of Chinese Medicine. A total of 47 patients with average age …
Umbilical Cord Blood Stem Cells Current Status & Future Potential Natasha Ali Assistant Professor Haematology Department of Pathology & Laboratory Medicine/Oncology The Aga Khan University
ORLANDO, Florida, January 30 /PRNewswire/ -- John Wagner, M.D., recognized as a leader in the field of cord blood stem cell transplantation, has joined the team at CORD:USE Cord Blood Bank. Dr. Wagners extensive experience and knowledge in transplant medicine and stem cell biology will provide a significant contribution to CORD:USE.
TY - JOUR. T1 - Concurrent acute necrotizing adenovirus hepatitis and enterocolitis in an adult patient after double cord blood stem cell transplant for refractory. AU - Disease, Crohns. AU - Lo, Amy A.. AU - Lo, Edward C.. AU - Rao, M. Sambasivia. AU - Yang, Guang Yu. PY - 2015/5/1. Y1 - 2015/5/1. N2 - It has been recently recognized that adenovirus is a pathogen with high morbidity and mortality among immunocompromised patients, particularly after solid organ or stem cell transplant. Confluent necrotizing hepatitis secondary to adenovirus infection alone or together with other organ involvement is extremely rare. There are only 32 cases of confluent necrotizing hepatitis reported in adults since 1960 and most occur after iatrogenic immunosuppression for bone marrow or solid organ transplantation or in other states of immunosuppression, including acquired immunodeficiency syndrome or chemotherapy treatment. We present the first case of concurrent adenovirus-induced necrotizing hepatitis and ...
The main purpose of this investigational (not approved by the FDA) Phase I research is to test whether transplantation of umbilical cord blood cells can
Our data indicate that UCBT is an excellent option for children with hereditary bone marrow failure syndromes when the donor is an HLA-matched sibling donor. Our results are in agreement with those of a previously published analysis which compared outcome of patients undergoing HLA-identical sibling UCBT with that of HLA-identical sibling bone marrow transplant recipients and showed similar overall survival in children with malignant and non-malignant diseases.16 Banks of related cord blood have been established; they are not, however, sufficiently developed despite the excellent results observed not only in marrow failure but also in other hereditary disorders such as hemoglobinopathies, metabolic disorders and congenital immune deficiencies.17,18 Another factor in favor of freezing cord blood cells from an HLA-identical sibling is the absence of risk for the donor.. An important observation is that the risk of graft failure after unrelated UCBT was high in this cohort of patients. The risk of ...
Promising results of umbilical cord blood transplantation (UCBT) from unrelated donors have been reported in patients with hematologic disorders. These transplants, having potential to trigger beneficial donor-versus-recipient natural killer (NK) cell-mediated alloreaction, we have conducted the fir …
Background: Measures were introduced in both the House and Senate to establish a National Cord Blood Stem Cell Bank Network.. Umbilical cord blood stem cells are obtained from the blood contained in the delivered placenta and umbilical cord, which are normally discarded after childbirth. Obtaining these stem cells presents no inherent moral concerns. Through freezing they can be preserved for many years.. According to findings presented in the House measure, cord blood stem cell transplants can be used for bone marrow reconstitution to treat malignancies such as leukemia and lymphoma, genetic disorders such as sickle cell anemia, and acquired diseases. The findings also claim that cord blood stem cells do not have to be matched as closely as bone marrow transplants. This means patients will be more likely to find a suitable unrelated cord blood donor than a matched bone marrow donor. Supporters say a network of at least 150,000 units of ethnically balanced cord blood donors would provide ...
Cell dose is a critical determinant of outcomes in unrelated cord blood (CB) transplantation. We investigated a strategy in which CB units should contain at least 2 × 107 total nucleated cells/kg of recipient weight, otherwise a second unit had to be added. We report the results of a study that was prematurely closed owing to toxicity. Patients with advanced hematologic malignancies without a human leukocyte antigen-matched sibling or unrelated donor were eligible. Conditioning regimen consisted of fludarabine and 12 Gy of total body irradiation (n=11), or melphalan (n=4), with antithymocyte globulin. Graft-versus-host disease prophylaxis was tacrolimus and methotrexate. Fifteen patients with acute leukemia (n=9), chronic myelogenous leukemia (n=2), multiple myeloma (n=2) and lymphoma (n=2) were treated; 60% had relapsed disease at transplantation. Three patients received double CB transplants. The 100-day and 1-year treatment-related mortality rates were 40 and 53%, respectively. Median time to
ATLANTA —Twelve percent of adults with acute myeloid or acute lymphoblastic leukemia who received umbilical cord blood transplantation experienced graft failure, according to a large European retrospective study presented at the ASH Annual Meeting and Exposition.“Our aim was to assess the outcomes of patients with acute leukemia who experience graft failure after umbilical cord blood
Clinical trial for Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation. , Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation
... ORLANDO Fla. Jan. 30 /- John Wagner M.D. recogniz... Were honored and fortunate to have him as a member of ourdistinguis...Dr. Wagner is internationally recognized as an expert in the field of...Dr. Wagner has played a considerable role in the development andexpan...,CORD:USE,Cord,Blood,Bank,Announces,the,Addition,of,Dr.,John,Wagner,,a,Pioneer,in,the,Use,of,Umbilical,Cord,Blood,Stem,Cells,,to,Its,Scientific,Advisory,Board,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
This clinical trial studies intra-osseous donor umbilical cord blood and mesenchymal stromal cell co-transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy and total-body irradiation before a co-transplant of donor umbilical cord blood and mesenchymal stromal cells into the bone (intra-osseous) helps stop the growth of cancer cells. It may also stop the patients immune system from rejecting the donors stem cells. The donated stem cells may replace the patients immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).
Haematopoietic stem cell transplants have been performed for more than 50 years and have been used to treat more than 80 life-threatening diseases
Stem cells hold the promise of treatments and cures for more than 70 major diseases.Dating back to the worlds first successful bone marrow transplant in 1968, the University of Minnesota Medical School has been, and continues to be, a leader in stem cell research and regenerative medicine-a field of innovative therapies that enable the body to heal itself.Now with new discoveries being made, were working on cures for everything from diabetes to dementia. The Medical Schools blood and marrow transplant research has a legacy of changing perspectives around what is medically possible for children battling some of the worlds most complex, life-threatening diseases. Beyond the first successful bone marrow transplant (BMT) in the world, the Medical School has a history of firsts, including:The first transplant to treat a patient with lymphoma (1975)The first transplant to treat an inherited metabolic disease (1982)The first double umbilical cord blood transplant (1999)The first umbilical cord blood
TY - JOUR. T1 - Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. AU - AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation. AU - Arai, Yasuyuki. AU - Takeda, June. AU - Aoki, Kazunari. AU - Kondo, Tadakazu. AU - Takahashi, Satoshi. AU - Onishi, Yasushi. AU - Ozawa, Yukiyasu. AU - Aotsuka, Nobuyuki. AU - Kouzai, Yasuji. AU - Nakamae, Hirohisa. AU - Ota, Shuichi. AU - Nakaseko, Chiaki. AU - Yamaguchi, Hiroki. AU - Kato, Koji. AU - Atsuta, Yoshiko. AU - Takami, Akiyoshi. PY - 2015/7/16. Y1 - 2015/7/16. N2 - Cord blood transplantation (CBT) is an effective therapeutic option for adults with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after the conventional cyclophosphamide and total body irradiation (CY/TBI) regimen, but posttransplant relapse is still of high importance. High-dose cytarabine (HDCA) can be added to CY/TBI for an intensified regimen; however, its additional effects have ...
Tens of thousands of patients need bone marrow transplants (BMT) every year, some for bone marrow (BM) cancers and some for inherited diseases such as sickle cell anemia and thalassemia, but many lack a BM donor. African Americans, Asian Americans, and people of Hispanic descent are more likely than others to lack a stem cell donor. BMTs provide hematopoietic (blood) stem and progenitor cells (HS/PCs) that replace the patients diseased BM with healthy BM. The new BM provides all the circulating blood cells throughout life. Many BMTs use HS/PCs that do not come from the BM. One such other source is umbilical cord blood (UCB). UCB HS/PCs have many advantages over other HS/PC sources (i.e., BM or peripheral blood). For example, we can easily obtain UCB HS/PCs without any risk to the donor, and we can keep the cells stored in freezers to be available when a patient needs them. However, most UCB samples contain too few HS/PCs to be used to treat people. Expanding the number of HS/PCs in UCB ...
Cord Blood Awareness Month is celebrated every July. Every couple out there, newlyweds or not, should have the right to be properly informed either to stored their newborns umbilical cord or donate it in public cord banks. However, the biggest problem until now is - this simple process of collecting stem cells embraces various misconceptions and controversies. Some people who are not well-informed about this procedure think it is unethical and some mistakenly associate it with embryonic stem cell.. The cord blood stem cells are entirely different from embryonic stem cells. In cord blood, you only use the stem cell found in babys umbilical cord. When a baby is delivered, the doctor removes his umbilical cord and placenta. Instead of throwing it away, the blood (which contains stem cells) inside the cord and placenta is squeeze out using a syringe and store in a fridge. Collecting cord blood is a safe procedure and it will not hurt the mother or the baby. In fact, this procedure is performed ...
Aarogya.com is Leading comprehensive health portal. This site has covered almost all the medical specialties and give useful information on various diseases.
Cord blood stem cell application is increasing a faster rate than other stem cell techniques because of its efficient and cost effective treatment p
You are being asked to take part in this study because you are going to have a cord blood transplant and one or more of the cord blood units that are considered by your doctor to be the best choice for your transplant may not meet all the new FDA standards. This study will allow your doctor to use these cord blood units for your transplant. Cord blood units used for transplant on this study must meet standards set by the NMDP. If a cord blood unit meets NMDP standards this means that the cord blood unit is suitable for use. This does not however guarantee that the cord blood units(s) will be successful in treating your disease ...
Front Pharmacol. 2017 Sep 8 Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies. Galieva LR1, Mukhamedshina YO1,2, Arkhipova SS1, Rizvanov AA1. Author information Abstract At present there is no effective treatment of pathologies associated with the death of neurons and glial cells which take place as a result of physical trauma or ischemic lesions of the nervous system. Thus, researchers have high hopes for a treatment based on the use of stem cells (SC),
Diabetes mellitus (DM) instigates a cascade of events leading to vascular damage and poor recovery after ischemic stroke. Our previous studies have found that treatment of stroke with bone-marrow-stromal cells initiated at 24h after stroke improves functional recovery in non-DM rats, but not in DM rats. Effective therapy for stroke in the non-DM population may not necessarily transfer to the DM population, prompting the need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke in the DM population. In this study, we hypothesize that treatment of stroke with human umbilical cord blood cells (HUCBCs) promotes neurorestorative effect in DM rats.. Methods: Type one DM (T1DM) was induced with a single injection of streptozotocin (60 mg/kg, ip) to adult male Wistar rats. These rats were subjected to 2h MCAo and were randomized to intravenous injection via tail-vein with: 1) phosphate-buffered saline control; 2) HUCBCs (5x106) at 24 hours after MCAo. A ...
As most parents would like to bank their babies cord blood to help safeguard their families, it is often the cost of cord blood banking that is the one reason why they do not. Most cord blood banks have an upfront fee for collecting, processing and cryo-preserving the cord blood that runs between $1,000 and $2,000. This upfront fee often also includes the price of the kit provided to collect and safely transport the cord blood, the medical courier service used to expedite the kits safe shipment, the testing of the mothers blood for any infectious diseases, the testing of the babys blood for any contamination, and the cost of the first full year of storage. There is then often a yearly fee on the babys birthday for continued storage that runs around $100 to $200 a year ...
As noted, there are different ways to process cord blood, and although the type of processing method doesnt always enter the conversation on cord blood banking, it is a big part of the purity of any cord blood collection. Red blood cells can have a negative impact on a cord blood transfusion. In addition, there is a certain number of stem cells that need to be present in order for the cord blood to be effective in disease treatment. Each processing method has the ability to better reduce the number of RBCs and capture more stem cells. Some processing methods like AutoXpress and Sepax are automated to ensure a level of consistency across all collections. HES is preferred by some banks because it was the original processing method used by most banks and it has a proven track record. You can read more about the different cord blood processing methods here ...
Although cord blood is currently considered discarded human material, it should only be collected for banking with an institutional review board-approved protocol and with signed informed consent from a parent.42,43 Pertinent donor information communicated to the cord blood bank should be kept confidential by the cord blood bank and used only to report important medical information obtained during the cord blood collection, processing, and screening process that is relevant to the safety of the donor and family. If cord blood was collected from a newborn who subsequently developed a genetic, immunologic, or malignant neoplastic disorder, parents should notify the cord blood bank so that the unit is not used for transplantation. All cord blood units banked for potential use should be tested for infectious diseases, similar to those tested in a blood bank, and for hereditary hematologic diseases. The informed consent must contain information pertaining to what tests are to be performed on the cord ...
In the United States, approximately 15 percent of children suffer from low or high-frequency hearing loss.[i] The most common type of hearing loss, especially at high frequencies, is sensorineural. Acquired sensorineural hearing loss results from damage to hair cells in the inner ear (cochlea) and can be caused by illness, medication, noise exposure, birth injury, or head trauma. A childs ability to hear affects the development of language skills, and hearing impairments can lead to poor academic and social development.[ii]. The groundbreaking phase 1 study has a primary objective of determining the safety of using cord blood stem cells in a select pediatric patient population while also assessing whether this approach to treatment improves inner ear function, speech, and language development. Researchers will follow 10 children, ranging in age from 6 weeks to 6 years, who have been diagnosed with acquired hearing loss for less than 18 months and who have their own cord blood unit processed and ...
Umbilical cord blood (UCB) is an alternative hematopoietic stem cell (HSC) source that can ameliorate several diseases through transplantation. The purpose of this project is to analyze clinical studies comparing HSCs from a single cord blood unit (CBU) to HSCs from bone marrow, and to explore methods of increasing limited amounts of HSCs. It was found that UCB transplantation in adults is a viable method when a matched bone marrow transplant cannot be identified. Further clinical studies using two CBUs suggest better engraftment and lower risk of relapse. However, double cord blood transplantation has been faced with the challenge of single unit dominance in most studies. Ex vivo expansion of UCB HSCs is another promising method to overcome limited HSC counts.
It makes more sense to donate】. Base on the current development of biomedical science, AAP discourage saving umbilical cord blood as a life insurance, because there are no scientific data as of now to support the use of autologous cord blood transplant. Though theoretically possible, we are uncertain whether the theory will become practice at all, or when exactly will this technology be adopted. Most private banks prey on the parents fear of the unknown future, knowing how vulnerable the parents are to the emotional effects of the marketing of cord blood banking. They advertise the many possibility as a reality despite there being a lot of uncertainties still.. Contrarily, there are many successful cases of allogeneic cord blood transplantation. In such cases, the stem cells transplanted are from other individuals. Majority of these stem cell transplants have been done using samples from public banks because a perfect match is not required for cord blood transplantation. This also shows why ...
by APFLI , Feb 2, 2006 , Stem Cell Research & Cloning. www.ClinicalTrials.gov - Amazing list of over 250 grants through NIH; at least half deal with non-embryonic stem cell research. http://www.clinicaltrials.gov/ct/search?term=%22stem+cells%22&submit=Search With patients own cells, heart vessels and tissue show mending http://www.chron.com/cs/CDA/ssistory.mpl/metropolitan/3277225 Check the Score http://stemcellresearch.org/ Diseases Treated Now with Cord Blood Stem Cells http://www.viacord.com/what_diseases_treated.htm Why Cord Blood is the Premier Source of Stem Cellshttp://www.viacord.com/what_why_premier_source.htm Adult & Umbilical Cord Blood Stem Cell Research Breakthroughs, Treatments and Cures as of 4/05 Spinal Cord Injuries - olfactory glial cells from the lining of the patients nose (1,2) or from umbilical cord stem cells (3) Skull Bone Repair - girls own bone and adult stem cells to repair 19 sq in. of her skull (4) Liver Repair - adult stem cells (5) Heart Muscle Regeneration - ...
by APFLI , Feb 2, 2006 , Stem Cell Research & Cloning. www.ClinicalTrials.gov - Amazing list of over 250 grants through NIH; at least half deal with non-embryonic stem cell research. http://www.clinicaltrials.gov/ct/search?term=%22stem+cells%22&submit=Search With patients own cells, heart vessels and tissue show mending http://www.chron.com/cs/CDA/ssistory.mpl/metropolitan/3277225 Check the Score http://stemcellresearch.org/ Diseases Treated Now with Cord Blood Stem Cells http://www.viacord.com/what_diseases_treated.htm Why Cord Blood is the Premier Source of Stem Cellshttp://www.viacord.com/what_why_premier_source.htm Adult & Umbilical Cord Blood Stem Cell Research Breakthroughs, Treatments and Cures as of 4/05 Spinal Cord Injuries - olfactory glial cells from the lining of the patients nose (1,2) or from umbilical cord stem cells (3) Skull Bone Repair - girls own bone and adult stem cells to repair 19 sq in. of her skull (4) Liver Repair - adult stem cells (5) Heart Muscle Regeneration - ...
Newborn Blood Banking stores umbilical cord blood stem cells as an alternative to bone marrow. We store whole blood to maximize the number of stem cells.
Newborn Blood Banking stores umbilical cord blood stem cells as an alternative to bone marrow. We store whole blood to maximize the number of stem cells.
Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication ...
Although pharmacological methods for treating AD have been discovered, none significantly delay the progression of the disease. However, cell transplantation research using animals modeled with AD has indicated that human umbilical cord blood cells (HUCBCs) can ameliorate some cognitive deficits and reduce the effects of the amyloid-beta (Aβ) plaques, one of the physiological hallmarks of AD, comprised of peptides of 36-43 amino acids. However, the role that HUCBCs play in Aβ clearance has yet to be elucidated ...
There are several advantages of using umbilical cord blood stem cells over bone marrow stem cells for transplants (see Table 2). The first advantage is that umbilical cord blood is relatively easy to collect and process. Once considered a substance to be thrown away after a birth, now the cord blood can be easily saved. After it is saved and sent to a storage facility, the cord blood is quickly available for use within days to weeks after processing. In contrast, bone marrow stem cells can take much longer to find a match, collect the sample, and process. The process for bone marrow transplantation can take from weeks to months. The collection process for cord blood is not painful to either mother or child and can be done either prior to or after the delivery of the placenta (Gonzalez-Ryan, VanSyckle, Coyne, & Glover, 2000; Percer, 2009). Bone marrow transplants, on the other hand, require the donor to be hospitalized, anesthetized, and experience postcollection pain and discomfort. Thus, ...
OBJECTIVE We examined the therapeutic strategies for treating mild gastrointestinal (GI) graft-versus-host disease (GVHD) using oral beclomethasone dipropionate (BDP) in 15 Japanese patients based on the donor source. The primary objective was to determine the efficacy and toxicity of oral BDP combined with/without low-dose prednisone (PSL). METHODS Oral BDP was administered with 1 mg/kg/d of PSL in patients undergoing bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT; n=11), and the dose of PSL was tapered off after 22 days. Oral BDP alone was administered in patients undergoing cord blood stem cell transplantation (CBSCT; n=4). The primary endpoint was the rate of treatment success on day 49, as measured according to the improvement or complete resolution of GI symptoms without additional treatment. The secondary endpoints included treatment-related toxicity according to the National Cancer Institute Common Toxicity Criteria version 3.0, the rate of treatment
Diabetes mellitus (DM) is a high risk factor for stroke and leads to more severe vascular and white-matter injury than stroke in non-DM. We tested the neurorestorative effects of delayed human umbilical cord blood cell (HUCBC) treatment of stroke in type-2 diabetes (T2DM). db/db-T2DM and db/+-non-DM mice were subjected to distal middle cerebral artery occlusion (dMCAo) and were treated 3 days after dMCAo with: (a) non-DM + Phosphate buffered saline (PBS); (b) T2DM + PBS; (c) T2DM + naïve-HUCBC; (d) T2DM + miR-126(-/-) HUCBC. Functional evaluation, vascular and white-matter changes, neuroinflammation, and miR-126 effects were measured in vivo and in vitro. T2DM mice exhibited significantly decreased serum and brain tissue miR-126 expression compared with non-DM mice. T2DM + HUCBC mice exhibited increased miR-126 expression, increased tight junction protein expression, axon/myelin, vascular density, and M2-macrophage polarization. However, decreased blood-brain barrier leakage, brain hemorrhage, and miR
American Cancer Society: Bone Marrow and Peripheral Blood Stem Cell Transplants - The American Cancer Society is the nationwide community-based voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer, saving lives, and diminishing suffering from cancer, through research, education, advocacy, and service. Learn the basics and read the transplant process at this site.. The Bone Marrow Foundation - The mission of The Bone Marrow Foundation is to improve the quality of life for bone marrow and stem cell transplant patients and their families by providing financial aid, education and emotional support.. BMT InfoNet - Blood & Marrow Transplant Information Network is a not-for-profit organization dedicated exclusively to serving the needs of persons facing a bone marrow, blood stem cell or umbilical cord blood transplant. Here you will find support services, a drug database and more.. Cancer.Net: Understanding Bone Marrow and Stem Cell ...
Chatchada Karanes, M.D., is a hematologist/oncologist at City of Hope specializing in stem cell transplantation with an emphasis on the use of umbilical cord blood transplants to treat a growing number of blood cancers.
A bone marrow transplant is a treatment option for some people who have life-threatening blood or immune system diseases, such as leukaemia, multiple myeloma and lymphoma. The procedure replaces blood stem cells in people whose bone marrow has been destroyed by large doses of chemotherapy or radiotherapy.. A bone marrow transplant is a generic term that covers all types of transplants that use stem cells: a blood stem cell transplant, an umbilical cord blood transplant and a bone marrow transplant.. There are different types of bone marrow transplants:. ...
Umbilical cord blood is taken from a new-borns umbilical cord and placenta immediately following birth - a painless, risk-free procedure. Cord blood contains a high concentration of stem cells, and recent studies have shown it provides unique advantages over traditional bone-marrow transplantation. The most significant advantage is that the donor cord blood stem cells do not have to match 100% to the recipients tissue, making finding a suitable match easier.. Cord blood can be used for the baby, the brothers and sisters and the mom and dad with a suitably matching tissue type, and in these instances cord blood stem cell transplants can in fact prove life-saving.. Much like cord blood, umbilical cord tissue can also be collected and stored in a stem cell bank. Cord tissue Mesenchymal stem cells (MSCs) are younger and considered a superior resource when compared to bone marrow MSCs as they are younger and subsequently, they have greater differentiation potential and faster rates of ...
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving
HONG KONG, July 23, 2014 /PRNewswire-FirstCall/ - China Cord Blood Corporation (NYSE: CO) (CCBC or the Company), Chinas leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, and Cordlife Group Limited (Cordlife), a multi-product healthcare company catering to the mother and child segment, today announced that the two companies have joined forces in assisting patients across the PRC, Singapore, Hong Kong, Indonesia, India, the Philippines and Malaysia to identify suitable cord blood matching units for stem cell therapy. Under the Memorandum of Understanding signed between the two companies, Cordlife, on behalf of its patients who are in need of cord blood stem cell therapy, can facilitate the process by providing relevant information to CCBC, who will then perform searches for possible matching units among its donated cord blood samples in the PRC. For patients who reside in the PRC, CCBC may seek Cordlifes ...
Since 1988, allogeneic cord blood transplantations have been used in the hematology and oncology area. Cord blood banks, either public or from non-profit corporations, opened in several countries. They organized themselves into a world-wide network permitting broad and quick graft availability all over the world. Cryopreservation modalities and biological safety were strongly defined according to laboratory good practices. More recently, in the United States, Canada and some European and Asian countries, commercial companies created for-profit cord blood banks. They offer families the possibility of privately storing the cord blood of their children. Then, if a child gets sick and needs a hematopoietic stem cell transplantation, it is possible to use the cord blood for an autograft. These companies present this service, relatively expensive for the families, as a true biological insurance. Also, they capitalize on families hopes that scientific progress will increase cord blood autografts and ...
It is wonderful to pretend that supporters of embryonic stem cell research oppose funding of other types of research, but it is patently a lie. It is generally only those who oppose embryonic stem cell research who oppose funding of any particular type of stem cell research. ...
blogs, forum,discussion,music promotion,hip hop,events,TheBlackList,packing and moving,trekking,news,current events,pan african,civil rights,african american, caricom,rastafari,rastafarian,black conservatives,black republicans,afrika,reparation
Therapeutic Benefit of Treatment of Stroke with Simvastatin and Human Umbilical Cord Blood Cells: Neurogenesis, Synaptic Plasticity and Axon Growth
Rizvanov, AA., Guseva, DS., Salafutdinov, II., Kudryashova, NV., Bashirov, FV., Kiyasov, AP., Yalvaç, ME., Gazizov, IM., Kaligin, MS., Sahin, F., Mukhamedyarov, MA., Palotás, A., Islamov, RR. Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice. Exp Biol Med. 236 (1):91-98. 2011 ...
... is amongst the diseases treated with bone marrow transplantation and cord blood stem cells.[citation needed] WHIM ... Myelokathexis is a congenital disorder of the white blood cells that causes severe, chronic leukopenia (a reduction of ... circulating white blood cells) and neutropenia (a reduction of neutrophil granulocytes). The disorder is believed to be ... Blood. 95 (1): 320-327. PMID 10607719. Hord, JD; Whitlock, JA; Gay, JC; Lukens, JN (Sep-Oct 1997). "Clinical features of ...
Jane Dreaper (13 May 2005). "Concern over cord blood banking". BBC News. Retrieved 24 March 2016. "New cord blood stem cell ... "Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For ... It procures, processes and stores human umbilical cord blood and tissue samples that may be used for stem cell treatments. ... "5 things to think about when banking your baby's stem cells". Cord Blood Aware. 29 January 2016. Retrieved 24 March 2016. ...
... and not pluripotent stem cells (such as embryonic stem cells, which can differentiate into any type of tissue). Cord blood has ... hematopoietic cell transplantation stem cell transplantation (4th ed.). Oxford: Wiley-Blackwell. ISBN 9781444303537. Haller M J ... Along with cord blood, Wharton's jelly and the cord lining have been explored as sources for mesenchymal stem cells (MSC), and ... Any such potential beyond blood and immunological uses is limited by the fact that cord cells are hematopoietic stem cells ( ...
Transplantation of stem cells are taken from the bone marrow, peripheral blood or umbilical cord of healthy, matched donors. ... Hematopoietic stem cells give rise to blood cells. Differentiation and proliferation of hematopoietic stem cells require a lot ... Stem cells are taken from an affected child's blood or bone marrow. Then in laboratory conditions the stem cells are ... Hematopoietic Stem Cell Transplantation (HSCT) involves intravenous infusion of stem cells to those who have either a damaged ...
Search & Match tool: The BMDW provides a fast preliminary search tool to find the best matched stem cell donor or cord blood ... The tool is primarily intended for use by professionals in the field of stem cell transplantation with profound knowledge of ... The purpose of BMDW still remains the same, to collect the HLA phenotypes of volunteer stem cell donors and cord blood units ... BMDW's mission is to create a comprehensive, fair, and equitable global list of unrelated stem cell donors and cord blood ...
... or umbilical cord blood.[1][2] It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... Peripheral blood stem cells[25] are now the most common source of stem cells for HSCT. They are collected from the blood ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ...
"Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation". Blood. 117 (10): 2791-9. doi:10.1182/blood- ... StemCyte began collaborations with Cord blood banks worldwide to systematically screen Umbilical cord blood samples for the ... "Progress toward curing HIV infection with hematopoietic cell transplantation". Stem Cells and Cloning. 8: 109-16. doi:10.2147/ ... "Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation". The New England Journal of Medicine. 360 (7): 692- ...
June 2008). "Stem cell transplantation for primary immunodeficiencies". Bone Marrow Transplant. 41 Suppl 2: S83-6. doi:10.1038/ ... new methods have reduced culture time to 10-12 days by using specific cytokines from adult donors or virus-naive cord blood. ... cell responses to mitogens and allogeneic cells, cytokine production by cells Tests for B cell function: antibodies to routine ... Virus-specific T-Lymphocytes (VST) therapy is used for patients who have received hematopoietic stem cell transplantation that ...
... and stores umbilical cord blood for the purpose of clinical cures and basic research in the field of stem cell transplantation ... cord blood collection and processing, distribution of the cord blood units, and evaluation of transplant outcomes. "Revenue ... cord blood, organ and tissue. The Foundation works with blood centers, organ procurement organizations, marrow registries and ... LifeCord participates in the network of public cord blood banks affiliated with the National Marrow Donor Program's Be The ...
Updated: 16 December 2013 Why Perform a Stem Cell Transplant? *^ Bone Marrow Transplantation and Peripheral Blood Stem Cell ... Stem cells can also be taken from umbilical cord blood just after birth. Of all stem cell types, autologous harvesting involves ... mesenchymal stem cell, adipose-derived stem cell, endothelial stem cell, dental pulp stem cell, etc.).[37][38] Muse cells ( ... Stem cell division and differentiation A: stem cell; B: progenitor cell; C: differentiated cell; 1: symmetric stem cell ...
... is used the same way that hematopoietic stem cell transplantation is used to reconstitute bone marrow following ... The cord blood is composed of all the elements found in whole blood. It contains red blood cells, white blood cells, plasma, ... Collected cord blood is cryopreserved and then stored in a cord blood bank for future transplantation. Cord blood collection is ... Cord blood is being used to get stem cells with which to test in people with type 1 diabetes mellitus. The stem cells from ...
"Differentiation of endothelial progenitor cells from human umbilical cord blood CD 34+ cells in vitro". Acta Pharmacologica ... 2 (6). doi:10.1186/2040-2384-2-6. Rafil S, Lyden D (2003). "Therapeutic stem and progenitor cell transplantation for organ ... These parent stem cells, ESCs, give rise to progenitor cells, which are intermediate stem cells that lose potency. Progenitor ... red blood cells), megakaryocytes/platelets, mast cells, T-lymphocytes, B-lymphocytes, dendritic cells, natural killer cells, ...
... unless there is a family member with a current or potential need to undergo a stem cell transplantation. The American Academy ... However, cord blood stem cells (hematopoietic stem cells) are not embryonic stem cells (pluripotent stem cells). Cryo-Cell ... Cord blood stem cells are blood cell progenitors which can form red blood cells, white blood cells, and platelets. This is why ... Since then, cord blood has become increasingly recognized as a source of stem cells that can be used in stem cell therapy. ...
... endothelial stem cells (to form lining of blood vessels) from umbilical cord blood; and mesenchymal stem cells (to form ... A proof-of-concept of using induced pluripotent stem cells (iPSCs) to generate human organ for transplantation was reported by ... 2 July 2010). "Reprogramming of human peripheral blood cells to induced pluripotent stem cells". Cell stem cell. 7 (1): 20-4. ... Embryonic cord-blood cells were induced into pluripotent stem cells using plasmid DNA. Using cell surface endothelial/pericytic ...
... or umbilical cord blood. It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a ... Peripheral blood stem cells are now the most common source of stem cells for HSCT. They are collected from the blood through a ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... Umbilical cord blood is obtained when a mother donates her infant's umbilical cord and placenta after birth. Cord blood has a ...
Treatment options may include surgery, radiation therapy, chemotherapy, or stem cell transplantation. Even in cases in which ... Sex cord/Gonadal stromal tumors Leydig cell tumor Sertoli cell tumor Lipid rich variant Scleriosing variant Large cell ... This is because the lymphatic system of the scrotum, through which white blood cells (and, potentially, cancer cells) flow in ... mixed types Mixed Germ Cell and Sex Cord/Gonadal Stromal Tumors Gonadoblastoma Germ cell-sex cord/gonadal stromal tumor, ...
"Stem Cell Transplant (Peripheral Blood, Bone Marrow, and Cord Blood Transplants)". Retrieved 4 March 2012. "Peripheral Blood ... Peripheral blood stem cell transplantation (PBSCT), also called "Peripheral stem cell support", is a method of replacing blood- ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem cells (Dayton, Ohio). 19 (2): 108-17. doi:10.1634/ ... CD34+ cells) yield. Immature blood cells hematopoietic stem cells in the circulating blood that are similar to those in the ...
... peripheral blood stem cells collected by apheresis, and umbilical cord stem cells. By 2016, this has grown to over 13,000 stem ... On January 13, 2011, City of Hope performed its 10,000th hematopoietic stem cell transplantation, which includes transplants of ... contract to facilitate stem cell research from laboratory to clinical study; focus on development and manufacture of stem cell ... Joy, Darrin S. (2009-12-14). "City of Hope receives $17 million for islet and stem cell informatics". City of Hope - Hope News ...
Only Hematopoietic Stem Cell Transplantation (HSCT), commonly referred to as a bone marrow or (umbilical) cord blood transplant ... high white blood cell count in blood), absolute monocytosis (high monocyte count in blood), anemia (low red blood cell count in ... Immature granulocytes and nucleated red cells in the peripheral blood. White blood cell count >10 x 109/L. Clonal chromosomal ... The only treatment that has resulted in cures for JMML is stem cell transplantation, also known as a bone marrow transplant, ...
... stem cell factor and rhIL-4 stimulate differentiation and proliferation of CD3+ cells from umbilical cord blood and CD3+ cells ... "Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantation". Bone Marrow ... "In vitro differentiation of endothelial cells from AC133-positive progenitor cells". Blood. 95 (10): 3106-12. PMID 10807776. ... Hollenbeck ST, Sakakibara K, Faries PL, Workhu B, Liu B, Kent KC (August 2004). "Stem cell factor and c-kit are expressed by ...
The T-cells of umbilical cord blood (UCB) have an inherent immunological immaturity,[33] and the use of UCB stem cells in ... "Unrelated donor hematopoietic cell transplantation: Marrow or umbilical cord blood?". Blood. 101 (11): 4233-44. doi:10.1182/ ... 2019). "Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation ... Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 22 (5): 910- ...
"Cord Blood Banking for Potential Future Transplantation". "Cord blood yields 'ethical' embryonic stem cells.", Coghlin A. New ... to freeze for long-term storage at a cord blood bank should the child ever require the cord blood stem cells (for example, to ... 2005). "Anti-inflammatory effects of human cord blood cells in a rat model of stroke". Stem Cells Dev. 14 (5): 595-604. doi: ... Cord Blood for Neonatal Hypoxic-Ischemic Encephalopathy, Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy Study ...
Updated: 16 December 2013 Why Perform a Stem Cell Transplant? *^ Bone Marrow Transplantation and Peripheral Blood Stem Cell ... The FDA has approved five hematopoietic stem-cell products derived from umbilical cord blood, for the treatment of blood and ... and such research involves adult stem cells, amniotic stem cells, and induced pluripotent stem cells. ... Healthy adult brains contain neural stem cells which divide to maintain general stem-cell numbers, or become progenitor cells. ...
... A offer stem cell enriched cord blood repository services as well as stem cell enriched cord blood for transplantation ... Under ReliCord S the stored cord blood stem cells can be used for haematopoetic stem cell transplantation for family members ... culturing of mesenchymal stem cells and storage of cord tissue with 15 million stem cells. Before storage the cord blood is ... The stem cell enriched cord blood is then cryo-preserved at the repository at a temperature of minus 196 degrees Celsius. Stem ...
Sickle Cell and Thalassaemia, Stem Cell Transplantation (Vice-Chair), Sustainable Relationships (Secretary), Voice UK and Youth ... umbilical cord blood banking, treatment and research in his Parliament biography. Burrowes was a member of a number of All ... and Stem Cell Transplantation. David is also an officer of the following APPGs - Cyprus, Human Trafficking, Religious Education ... and Stem Cell Transplantation. David is also an officer of the following APPGs - Cyprus, Human Trafficking, Religious Education ...
... induced pluripotent stem cells, germ line stem cells, adult stem cells, cancer stem cells, and cord blood stem cells. The ... or internationally Use of adult stem cells in corneal injuries and myocardial infarction on human Transplantation of stem cells ... founded a Department of Stem Cells in 2002 to establish human embryonic stem cell lines and Induced Pluripotent Stem Cells ( ... one human embryonic stem cell line in International Society of Stem Cell Research Establishment of 6 human embryonic stem cell ...
... is therefore a potential source of adult stem cells (also see the more common method of storing cord blood). ... "Wharton's Jelly Transplantation Improves Neurologic Function in a Rat Model of Traumatic Brain Injury". Cell Mol Neurobiol. 35 ... Stem Cells. 2003;21(1):50-60. Wharton's Jelly, Hair Follicles New Sources of Adult Stem Cells, Studies Find StemCellNews.com, ... "Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes". Cell Immunol. ...
Sarhan, a former professor of pediatrics in the Bone Marrow and Stem Cell Transplantation Program at Duke University, was an ... The program oversees both matched allogeneic and autologous transplants and performs transplants utilizing cord blood, making ... He founded KHCC's bone marrow transplantation (BMT) program in 2003, a program which has become one of the largest and most ...
Bill Young Cell Transplantation Program and National Cord Blood Inventory, HRSA helps make possible blood stem cell transplants ... Stem cells for transplant come from adult volunteer donors and umbilical cord blood units donated to public cord blood banks. ... "What you must know about umbilical cord stem cells". U.S. Government Accountability Office, Report to Committees: Drug Pricing ... The program recruits adult volunteer donors, helps member cord blood banks collect and list additional units, and supports ...
... or umbilical cord blood.[1][2][3] It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come ... Cutler C, Antin JH (2001). "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. ... Peripheral blood stem cells[26] are now the most common source of stem cells for HSCT. They are collected from the blood ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ...
"Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics". Exp Cell Res ... Wu DC, Boyd AS, Wood KJ (2007). "Embryonic stem cell transplantation: potential applicability in cell replacement therapy and ... "Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese ... Lindvall O (2003). "Stem cells for cell therapy in Parkinson's disease". Pharmacol Res 47 (4): 279-87. PMID 12644384. ...
"Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell ... The inflammatory cells involved include neutrophil granulocytes and macrophages, two types of white blood cells. Those who ... vocal cords. Laryngopharyngeal reflux (LPR). Vocal fold nodule. Vocal fold paresis. Vocal cord dysfunction. epiglottis. ... Stopping smoking, respiratory rehabilitation, lung transplantation[2]. Medication. Vaccinations, inhaled bronchodilators and ...
Updated: 16 December 2013 Why Perform a Stem Cell Transplant?. *↑ Bone Marrow Transplantation and Peripheral Blood Stem Cell ... "A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved ... "Journal of Stem Cells and Regenerative Medicine.. *↑ "Index of CD34+ Cells and Mononuclear Cells in the Bone Marrow of Spinal ... name="nih",Stem Cell Basics: What are the potential uses of human stem cells and the obstacles that must be overcome before ...
Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proceedings of the ... KK Ballen, F Verter and J Kurtzberg Umbilical cord blood donation: public or private? Bone Marrow Transplantation (2015), 1-8 ... Increased migration of cord blood-derived CD34+ cells, as compared to bone marrow and mobilized peripheral blood CD34+ cells ... Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling ...
"Intraspinal stem cell transplantation for amyotrophic lateral sclerosis". Annals of Neurology. 79 (3): 342-53. doi:10.1002/ana. ... low oxygen in the blood) and hypercapnia (too much carbon dioxide in the blood).[14] If their daytime blood gas analysis is ... A few people with ALS have symptoms that are limited to one spinal cord region for at least 12 to 24 months before spreading to ... One 2016 review of stem-cell therapy trials found tentative evidence that intraspinal stem cell implantation was relatively ...
A rare population of hematopoietic progenitor cells enter the thymus from the blood, and expands by cell division to generate a ... derived from bone marrow resident hematopoietic stem cells). Developing T cells are referred to as thymocytes and are of ... but the neck of the flask persists for some time as a cellular cord. By further proliferation of the cells lining the flask, ... The newly formed organ resembled a normal thymus histologically and molecularly, and upon transplantation it was able to ...
Chemotherapy, stem cell transplantation, radiation therapy, targeted therapy[1]. Prognosis. Children: 90% five-year survival ... The excessive immature lymphocytes in the bone marrow interfere with the production of new red blood cells, white blood cells, ... Cancer spreading into the Central nervous system (brain or spinal cord) has worse outcomes. ... T cell or pre-B cell Large and heterogeneous (varied) cells ALL - L3 B cell Large and varied cells with vacuoles Mature B-cell ...
Successful photoreceptor transplantation, MIT Technology Review, November 2006. How stem cells might restore sight Technology ... The optic nerve carries the ganglion cell axons to the brain, and the blood vessels that supply the retina. The ganglion cells ... Cone-rod dystrophy (CORD) describes a number of diseases where vision loss is caused by deterioration of the cones and/or rods ... Cells. *Photoreceptor cells (Cone cell, Rod cell) → (Horizontal cell) → Bipolar cell → (Amacrine cell) → Retina ganglion cell ( ...
Hematopoietic stem cell transplantation (HSCT) with high intensity conditioning protocol has been performed in a few cases with ... The presence of antibodies against GAD is the best indication of the condition that can be detected by blood and cerebrospinal ... The antibodies appear to interact with antigens in the brain neurons and the spinal cord synapses, causing a functional ... There is a limited but encouraging therapeutic experience of hematopoietic stem cell transplantation for SPS. ...
Stem cell transplants are a recent research target, because stem cells are easy to manipulate and stem cells transplanted into ... Neural transplantation. Since early in the 1980s, fetal, porcine, carotid or retinal tissues have been used in cell transplants ... Dopamine does not cross the blood-brain barrier, so it cannot be taken as a medicine to boost the brain's depleted levels of ... Spinal cord. *Myelitis: Poliomyelitis. *Demyelinating disease *Transverse myelitis. *Tropical spastic paraparesis. *Epidural ...
Updated: 16 December 2013 Why Perform a Stem Cell Transplant? *↑ Bone Marrow Transplantation and Peripheral Blood Stem Cell ... Index of CD34+ Cells and Mononuclear Cells in the Bone Marrow of Spinal Cord Injury Patients of Different Age Groups: A ... Skin Cells Can Become Embryonic Stem Cells". National Public Radio.. *↑ „Breakthrough Set to Radically Change Stem Cell Debate" ... 2005) "Stem cells: their definition, classification and sources", Stem Cells: From Benchtop to Bedside. World Scientific. ISBN ...
Heart transplantation Organ donation Transplant surgery Brain stem death Non-heart-beating donation Legal death Clinical death ... Instead the spinal cord coordinates the knee-jerk reactions of reflexes including pulling back from the pain of putting a hand ... A beating heart cadaver requires a ventilator to provide oxygen to its blood, but the heart will continue to beat on its own ... The heart contains pacemaker cells that will cause the heart to continue beating even when a patient is brain-dead. Other ...
The living cells that can cause these movements are not living cells from the brain or brain stem, these cells come from the ... Also, a radionuclide cerebral blood flow scan that shows complete absence of intracranial blood flow must be considered with ... Since the 1960s, laws on determining death have, therefore, been implemented in all countries with active organ transplantation ... "Difficulty in brainstem death testing in the presence of high spinal cord injury". British Journal of Anaesthesia. 92 (5): 762 ...
... peripheral blood regulatory T-cells that may account for the significantly different responses after cord blood transplantation ... The PCRF currently awards grants in the following categories of research: Stem cell transplantation Stem cell biology Molecular ... Blood Institute for the establishment of an Umbilical Cord Blood Bank and Umbilical Cord Blood Transplant Center. In 1997, the ... Through the next couple years, the PCRF began to launch research in the areas of immunotherapy and stem cell biology. In 1994, ...
... from adult stem cells or progenitor cells would contribute to overcoming the shortage of donor organs for transplantation. The ... Hormones produced in the pancreatic islets are secreted directly into the blood flow by (at least) five types of cells. In rat ... activates beta cells and inhibits alpha cells. *Glycogen/Glucagon: activates alpha cells which activates beta cells and delta ... PP cells (gamma cells or F cells) producing pancreatic polypeptide (,5%). It has been recognized that the cytoarchitecture of ...
"Hyaluronic acid hydrogel for controlled self-renewal and differentiation of human embryonic stem cells". Proc. Natl. Acad. Sci ... and hyaluronic acid purified from human umbilical cord is 3,140,000 Da;[3] other sources mention average molecular weight of 7 ... and this protein may be responsible mainly for the clearance of HA from lymph and blood plasma, which accounts for perhaps most ... corneal transplantation, cataract surgery, glaucoma surgery, and surgery to repair retinal detachment). Other biomedical ...
Cardiovascular system: pumping and channeling blood to and from the body and lungs with heart, blood and blood vessels. ... The transplantation of larger solid organs often requires immunosuppression to prevent organ rejection or graft vs host disease ... In biology, tissue is a cellular organizational level between cells and complete organs. A tissue is an ensemble of similar ... For example, the liver evolved in the stem vertebrates more than 500 million years ago, while the gut and brain are even more ...
Mesenchymal Stem Cells and the Acute Respiratory Distress Syndrome. *v. *t. *e ... Low tidal volumes (Vt) may cause a permitted rise in blood carbon dioxide levels and collapse of alveoli[10] because of their ... fat emboli and reperfusion pulmonary edema after lung transplantation or pulmonary embolectomy. However, the majority of these ... Vocal cord dysfunction. epiglottis. Epiglottitis. trachea. Tracheitis. Laryngotracheal stenosis. Lower RT/lung disease. ( ...
2009). "Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase ... 2006). "Secondary degeneration reduced by inosine after spinal cord injury in rats". Spinal Cord 44 (7): 421-6. PMID 16317421. ... Oztaş B, Kiliç S, Dural E, Ispir T (November 2001). "Influence of antioxidants on the blood-brain barrier permeability during ... February 2008). "B-cell depletion with rituximab in relapsing-remitting multiple sclerosis". N Engl J Med. 358 (7): 676-88. ...
Peripheral Blood Stem Cells (PBSC):[8] It is possible to collect stem cells from the peripheral blood rather than the bone ... "The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation". Bone Marrow Transplantation. ... that operates the Be The Match Registry of volunteer donors and cord blood units. In May 2004, the Gift of Life Marrow Registry ... This mobilizes stem cells to travel from the bone marrow into the circulating blood. The stem cells are collected through a ...
... including umbilical cord blood.[66] Using genetic reprogramming, pluripotent stem cells equivalent to embryonic stem cells have ... has published a small case series of nine defects in five knees involving surgical transplantation of mesenchymal stem cells ... Hematopoietic stem cells[edit]. Main article: Hematopoietic stem cell. Hematopoietic stem cells (HSCs) are stem cells that can ... Stem cell division and differentiation. A - stem cells; B - progenitor cell; C - differentiated cell; 1 - symmetric stem cell ...
... stem cells in the blood of the donor before collection by leukapheresis for use in hematopoietic stem cell transplantation. For ... A combination of human G-CSF and cord blood cells has been shown to reduce impairment from chronic traumatic brain injury in ... Stem cell transplantsEdit. G-CSF may also be given to the receiver in hematopoietic stem cell transplantation, to compensate ... White blood cells. The G-CSF-receptor is present on precursor cells in the bone marrow, and, in response to stimulation by G- ...
... regeneration of red blood cells via erythropoiesis occurs through the maturation of erythrocytes from hematopoietic stem cells ... "Liver regeneration in recipients and donors after transplantation". Lancet. 339 (8793): 580-1. doi:10.1016/0140-6736(92)90867-3 ... "Regeneration of the radial nerve cord in the sea cucumber Holothuria glaberrima". BMC Developmental Biology. 9: 3. doi:10.1186 ... Macrophages are a type of repairing cell that devour dead cells and pathogens, and trigger other immune cells to respond to ...
Cell Stem Cell, 2016 Nov 3; 19 (5), pàg. 663-671. DOI: 10.1016/j.stem.2016.07.019. PMC: 5144538. PMID: 27524440 [Consulta: 3 ... A Three-Dimensional Cell Culture System To Model RNA Virus Infections at the Blood-Brain Barrier» (en anglès). mSphere, 2017 ... Ramalho, FS; Yamamoto, AY; da Silva, LL; Figueiredo, LT; et al «Congenital Zika virus infection induces severe spinal cord ... Kotton, CN «Zika Virus and Solid Organ Transplantation: Significant Pathogen or Harbinger of Things to Come?» (en anglès). ...
... in Shenzhen using Beikes proprietary cord blood stem cell transplantation protocol. ... Chinas leading stem cell research and regenerative medicine company, and Medistem, Inc.,reported positive safety data in 114 ... Study demonstrates safety of cord blood stem cell transplantation protocol to treat neurological conditions. *Download PDF Copy ... in Shenzhen using Beikes proprietary cord blood stem cell transplantation protocol.. The peer-reviewed paper is available at ...
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases. The ... Cord blood transplant: All patients undergo umbilical cord blood transplantation on day 0. ... RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by chemotherapy or ... Impact of the use of umbilical cord blood as a source of hematopoietic stem cells. *Comparison of the incidence of graft-vs- ...
The use of cord blood cells as hematopoietic stem cell grafts for patients with blood cancers receiving an allogeneic stem cell ... Epigenetically Reprogrammed Cells Generate Functional Cord Blood Stem Cells for Transplantation. By Jo Cavallo. Posted: 5/13/ ... of functional cord blood stem cells can be generated by epigenetically reprogramming dividing cord blood CD34-positive cells ... cord blood cells as hematopoietic stem cell grafts for patients with hematologic malignancies receiving an allogeneic stem cell ...
A new syndrome characterized by watery diarrhea has been identified in a group of patients who underwent cord blood stem cell ... Source Reference: Herrera A, et al "Cord colitis syndrome in cord-blood stem-cell transplantation" N Engl J Med 2011; 365: 815- ... The use of umbilical cord blood for hematopoietic stem cell transplantation has been associated with less severe graft-versus- ... has been identified in a group of patients who underwent cord-blood stem-cell transplantation and is characterized by watery ...
Results to date of umbilical cord blood transplantation in adult and fully mature adolescent patients are inferior to what is ... episodes) life-threatening infection, known to be curable with allogeneic stem cell. transplantation (to include, but not ... that will provide the patient with a higher stem cell dose than can be given with a single. umbilical cord blood infusion. The ... umbilical cord blood unit that contains more than 1.5 x 107 nucleated cells/kg. The second. reason for inferior outcome of ...
p,Hematopoietic stem cell transplantation provides life-saving therapy for thousands of patients each year. However, many ... We have developed molecules that, when added to stem cells isolated from umbilical cord blood, expand the number of stem cells ... umbilical cord blood could serve as a source of stem cells, but a single cord usually contains too few cells to repopulate an ... We therefore developed small, drug-like molecules that expand the stem cells and progenitor cells in cord blood. In murine ...
... using the transplantation of blood-forming stem cells. Cord blood stem cells have already been used in more than 35,000 ... Using stem cell from cord blood for a sibling (allogeneic). In an allogeneic transplant, stem cells are collected from a donor ... More cells, more life. Preclinical and clinical studies with stem cells from cord blood, umbilical cord tissue, and placental ... Who can benefit from cord blood stem cells treatment?. Treatment with own stem cells (autologous). An autologous treatment uses ...
Researchers at the Icahn School of Medicine at Mount Sinai have identified a new technique that causes cord blood (CB) stems ... cells to generate in greater numbers making them more useful in adult transplantation. ... and other blood-related disorders may benefit from life-saving treatment commonly used in pediatric patients. ... Cord blood stem cells have always posed limitations for adult patients because of the small number of stem cells present in a ...
Stem Cell Transplantation Program. *About Stem Cell Transplantation*Types of Stem Cell Transplantation*Information for New ... Advocates of stem cell research have sought an alternative to this approach out of the wish for their childs cord blood to be ... Stanford Medicine Division of Stem Cell Transplantation and Regenerative Medicine - In the Department of Pediatrics Site Nav ... The mission of the Binns Program for Cord Blood Research (BPCBR) is simple: to advance research into a wide array of blood and ...
Broxmeyer, H.E. (2010a). Will iPS Cells Enhance Therapeutic Applicability of Cord Blood Cells and Banking?. Cell Stem Cell 6, ... 2009). Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 5, 353-357. ... 2009). Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 5, 434-441. Abstract Article ... Cord blood hematopoietic stem cell transplantation (May 26, 2010), StemBook, ed. The Stem Cell Research Community, StemBook, ...
Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking ... Tissue Banking and Transplantation Industry: Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug ... Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development ... Kalorama Information has tackled the question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug ...
... as an alternative source of stem cells to bone marrow for allogeneic-related and unrelated hematopoietic transplantation. To ... date, almost 70 000 CB units are available for transplantation and more than 2000 CB transplants (CBT) have been perform … ... Umbilical cord blood (CB) has been rapidly established ... Cord Blood Stem Cell Transplantation / adverse effects * Cord ... Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results Bone Marrow ...
Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer. The safety and scientific ... The purpose of this study is to examine the immune system response to cord blood stem cell transplantation in adults with ... The purpose of this study is to evaluate the effectiveness of umbilical cord blood stem cell transplantation in adults with ... Umbilical cord blood is an important source of stem cells and can be used to treat blood and immune system disorders and ...
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases ... Childhood Langerhans Cell Histiocytosis , Leukemia , Sarcoma , Lymphoma , Protocol Specific , ... Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Brief ... Cord blood transplant: All patients undergo umbilical cord blood transplantation on day 0. - Graft-versus-host disease ...
Cord blood transplantation (UCBT) and non-T-cell-depleted stem cell transplantation from haploidentical donors (HAPLO) are both ... Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with ... Medical Park, Stem Cell Transplant Unit, Antalya, Turkey.. 12. Erasmus MC Cancer Institute, University Medical Centre, ...
Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for ... Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for ... infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF ... 1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF ...
... of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with Umbilical Cord Blood ... Although hematopoietic stem cell transplantation (HSCT) has been considered to be the only way for potential cure of relapsed ... She was treated with a toxicity reduced conditioning regimen and received direct intrabone cord blood transplantation (CBT) ... using a single unit of 5/6 HLA-matched cord blood as a graft source. Graft-versus-host disease prophylaxis was performed with a ...
... of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with Umbilical Cord Blood ... Although hematopoietic stem cell transplantation (HSCT) has been considered to be the only way for potential cure of relapsed ... F. Frassoni, F. Gualandi, M. Podestà et al., "Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a ... M. J. Laughlin, M. Eapen, P. Rubinstein et al., "Outcomes after transplantation of cord blood or bone marrow from unrelated ...
Peripheral stem cell transplantation or umbilical cord blood transplantation may be able to replace immune cells that were ... peripheral blood stem cell transplantation Procedure: umbilical cord blood transplantation Radiation: radiation therapy Phase 1 ... Combining either umbilical cord blood transplantation or peripheral stem cell transplantation with antiviral therapy may be an ... Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV ...
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic ... AdultAgedCord Blood Stem Cell TransplantationGraft vs Host DiseaseHumansLeukemia, Lymphocytic, Chronic, B-CellLymphomaMiddle ... TY - JOUR T1 - Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and ... Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic ...
... conditioning and allogeneic stem cell transplantation in children and adolescents with malignancies from unrelated cord blood ... conditioning and allogeneic stem cell transplantation in children and adolescents with malignancies from unrelated cord blood ... conditioning and allogeneic stem cell transplantation in children and adolescents with malignancies from unrelated cord blood ... conditioning and allogeneic stem cell transplantation in children and adolescents with malignancies from unrelated cord blood ...
Stem Cell Rev 2:155-162, 2006. Weiss. ML. , Troyer. DL. : Stem cells in the umbilical cord. . Stem Cell Rev. 2. :. 155. -. 162 ... Percutaneous transplantation of human umbilical cord blood-derived multipotent stem cells in a canine model of spinal cord ... Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buergers disease and ischemic limb ... Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. . Biol Blood Marrow ...
BACKGROUND: Reduced intensity stem cell cell transplantation (RIST) from unrelated umbilical cord blood (RI-UCBT) is a novel ... Infectious Complications in Patients Undergoing Reduced Intensity Stem Cell Transplantation (RIST) from Unrelated Umbilical ... Department of Hematology, Toranomon Hospital, Tokyo, Japan; Hematopoietic Stem Cell Transplantation Unit, National Cancer ... Cord Blood (RI-UCBT). Session Type: Publication Only Koichiro Yuji, Shigesaburo Miyakoshi, Daisuke Kato, Eiji Kusumi, Masahiro ...
... when transplanted into patients with blood malignancies. Umbilical cord blood (UCB) is a source of blood stem cells and their ... use to treat patients has been embraced worldwide since the first UCB stem cell transplant in 1988. ... These rare cells are lifesaving, and are often the last resort, ... There is an aura that surrounds stem cells and their use. ... Szilvassy S. Measuring stem cells in cord blood: The value of the CFU assay. Parents Guide to Cord Blood Foundation newsletter ...
These results suggest that ALC recovery is an important prognostic indicator for patients treated with cord blood and T cell- ... We retrospectively analyzed 65 consecutive patients treated at our institution with cord blood (n = 37) and haploidentical (n ... 28) transplantation with myeloablative fludarabine, melphalan, and thiotepa conditioning. Patients with lymphocyte recovery at ... Alternative donor stem cell transplantation from cord blood or haploidentical peripheral blood donors is increasingly being ...
There are several people whose stem cells have found to be extirpated or weakened due to some genetic or chronic disease. Such ... Cord Blood Stem Cells. These days, umbilical cord blood has been considered to be an easy and healthy stem cell source. Along ... white blood cells and red blood cells. Different stem cell sources are found today. The primary source pertaining to stem cells ... cord blood is found to be a good stem cell source which could be stored, processed and retrieved. Cord blood can be obtained ...
2) CB-MSC: 80 - 160 ml umbilical cord blood was harvested and processed likewise as above. (3) Stem cell transplantation: Both ... Eighty-two patients underwent the double transplantations of bone mesenchymal stem cell (BMSC) and human umbilical cord blood ... and umbilical cord mesenchymal stem cells (UMSC) in the treatment of progressive muscular dystrophy (PMD). METHODS A total of ... CONCLUSION The double transplantation of BMSC and CB-MSC is convenient, safe and effective in the treatment of progressive ...
Secondly, the use of cord blood reduces the risk of graft vs host disease. Cord Blood Stem Cell banks have been established in ... Dhot PS, Nair V, Swarup D, Sirohi D, Ganguli P. Cord blood stem cell banking and transplantation. Indian Journal of Pediatrics ... Stem cells have the ability to divide for indefinite periods in culture and to give rise to specialized cells. Cord blood as a ... Since then, the advantages of cord blood as a source of hematopietic stem cells for transplantation have become clear. Firstly ...
Animals , Blood Banks , Blood Specimen Collection , Cord Blood Stem Cell Transplantation/methods , Female , Histocompatibility ... Blood Specimen Collection / Cord Blood Stem Cell Transplantation / Animals Language: English Year: 2005 Type: Article ... Blood Specimen Collection / Cord Blood Stem Cell Transplantation / Animals Language: English Year: 2005 Type: Article ... as an alternative source for hematopoietic stem cell transplantation. Since the first related cord blood transplantation (CBT) ...
Athletes Foot Stem Cells - Cord Blood Stem Cells - Fundamentals Parkinsons Disease Surgical Treatment Genetics and Stem Cells ... Stem Cells - Cord Blood. Encyclopedia section of medindia gives general info about Cord Blood ... Bone Marrow Transplantation. Preferred Term is Hematopoietic stem cell transplantation. In this stem cell from bone marrow are ... Stem Cells - Fundamentals. Encyclopedia section of medindia gives general info about Stem Cells ...
The risks and efficacy of transplanting two varieties of stem cells into mouse cochlea have been evaluated by Japanese ... Stem Cells - Cord Blood Tinnitus Presbycusis Stem Cells - Fundamentals Parkinsons Disease Surgical Treatment Genetics and Stem ... Stem Cells - Cord Blood. Encyclopedia section of medindia gives general info about Cord Blood ... Bone Marrow Transplantation. Preferred Term is Hematopoietic stem cell transplantation. In this stem cell from bone marrow are ...
CBT with pretransplant anti-HLA antibodies using the database of Japan Society for Hematopoietic Cell Transplantation (JSHCT). ... remains a major complication of cord blood transplantation (CBT). Although the presence of pretransplant, donor-specific anti- ... Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord ... Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. J Clin Oncol. ...
Cell Biology / Peripheral Blood Stem Cell Transplantation / Mesenchymal Stem Cell Transplantation Type of study: Incidence_ ... Unrelated Donor Peripheral Blood Stem Cell Transplantation Combined with Umbilical Cord Mesenchymal Stem Cells in Patients with ... Mesenchymal Stem Cell Transplantation , Neoplasm Recurrence, Local , Peripheral Blood Stem Cell Transplantation , Retrospective ... Unrelated Donor Peripheral Blood Stem Cell Transplantation Combined with Umbilical Cord Me ...
Identification of miRNAs from stem cell derived microparticles in umbilical cord blood *Angeliki Xagorari ... Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood ... Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantation. Bone Marrow Transplant ... Elevation of platelet activation markers and chemokines during peripheral blood stem cell harvest with G-CSF. Stem Cells 2004; ...
  • Until now, patients receiving cord blood transplants to fight hematopoietic diseases were immune-suppressed in order to prevent a potentially devastating condition known as 'graft versus host. (news-medical.net)
  • To establish a commercially viable protocol to expand umbilical cord blood hematopoietic stem/progenitor cells (UCB HS/PCs) to significantly increase access to UCB HSC transplants. (ca.gov)
  • Tens of thousands of patients need bone marrow transplants (BMT) every year, some for bone marrow (BM) cancers and some for inherited diseases such as sickle cell anemia and thalassemia, but many lack a BM donor. (ca.gov)
  • Cord blood stem cells have already been used in more than 35,000 transplants worldwide to regenerate healthy blood and immune system. (cordbloodcenter.com)
  • Haematopoietic stem cell transplants (HSCT) have been performed for more than 50 years and have been used to treat or cure more than 80 potentially life-threatening blood related diseases like leukaemia, lymphoma and bone marrow failures. (cryo-save.co.za)
  • To date, more than 1 million blood stem cell transplants have been performed, with more than one third using cord blood stem cells. (cryo-save.co.za)
  • By 2013, private cord blood banks have released 530 samples for autologous transplants and 485 for allogeneic transplant. (cryo-save.co.za)
  • According to findings presented in the House measure, cord blood stem cell transplants can be used for bone marrow reconstitution to treat malignancies such as leukemia and lymphoma, genetic disorders such as sickle cell anemia, and acquired diseases. (humanlifeaction.org)
  • The findings also claim that cord blood stem cells do not have to be matched as closely as bone marrow transplants. (humanlifeaction.org)
  • Supporters say a network of at least 150,000 units of ethnically balanced cord blood donors would provide appropriate matches for at least 90% of those seeking these stem cell transplants. (humanlifeaction.org)
  • The fact that Beike has been able to demonstrate safety of transplant by manipulating an established stem cell source is a substantial advancement for the field. (news-medical.net)
  • The use of cord blood cells as hematopoietic stem cell grafts for patients with blood cancers receiving an allogeneic stem cell transplant has been limited to children due to the small number of stem cells present in a single cord blood collection. (ascopost.com)
  • Following the stem cell transplant, the median time to syndrome onset was 131 days, although in one patient onset was more than 300 days later. (medpagetoday.com)
  • Transplanting blood stem cells (often called bone-marrow transplant) provides a life-saving therapy for thousands of patients each year. (ca.gov)
  • Umbilical cord blood could provide one solution to this problem, but most cord blood samples contain too few cells to transplant into an adult. (ca.gov)
  • We are optimizing the molecules to increase stem-cell production and are testing these expanded cells in transplant models. (ca.gov)
  • In an allogeneic transplant, stem cells are collected from a donor and transplanted into the patient. (cordbloodcenter.com)
  • Finding a matching donor is the key to a successful allogeneic stem cell transplant. (cordbloodcenter.com)
  • Through the science of cord blood banking, cord blood can help nurture life, long after a baby's birth and provide a source of stem cells should the need ever arise for a stem cell transplant. (cordlifeindia.com)
  • It has been recently recognized that adenovirus is a pathogen with high morbidity and mortality among immunocompromised patients, particularly after solid organ or stem cell transplant. (northwestern.edu)
  • We present the first case of concurrent adenovirus-induced necrotizing hepatitis and enterocolitis in an adult patient after double cord stem cell transplant for refractory Crohn's disease. (northwestern.edu)
  • Dating back to the world's first successful bone marrow transplant in 1968, the University of Minnesota Medical School has been, and continues to be, a leader in stem cell research and regenerative medicine-a field of innovative therapies that enable the body to heal itself. (umn.edu)
  • The Medical School's blood and marrow transplant research has a legacy of changing perspectives around what is medically possible for children battling some of the world's most complex, life-threatening diseases. (umn.edu)
  • Medical School faculty began the first and only program in the world that offers blood and marrow transplant as a treatment for the most severe types of EB. (umn.edu)
  • Our clinical program is recognized as the second largest unrelated donor transplant programs in the country, and one of the largest umbilical cord blood transplant centers worldwide. (umn.edu)
  • An autologous treatment uses the patient's own stem cells. (cordbloodcenter.com)
  • Storing your child cord blood makes him anytime eligible for an autologous treatment. (cordbloodcenter.com)
  • Among the 215 patients with graft failure, 54 underwent a second allogeneic (n = 53) or autologous (n = 1) transplantation after a median of 62 days (range, 16-700) following the first UCBT. (healio.com)
  • In May this year, the CNN program Vital Signs featured a Duke University clinical trial evaluating the safety and feasibility of autologous cord blood infusion in young children with Autism Spectrum Disorder. (cryo-save.co.za)
  • The safety of autologous cord blood infusions in children with cerebral palsy and other acquired brain injuries have been demonstrated and when adequately dosed, significant improvement in motor function in young children with spastic cerebral palsy were observed. (cryo-save.co.za)
  • The study will use, for the first time in clinical research, autologous MSC derived from cryopreserved cord tissue. (cryo-save.co.za)
  • We therefore developed small, drug-like molecules that expand the stem cells and progenitor cells in cord blood. (ca.gov)
  • BMTs provide hematopoietic (blood) stem and progenitor cells (HS/PCs) that replace the patient's diseased BM with healthy BM. (ca.gov)
  • Thymic progenitor cells to enhance immune recovery and reduce the risk of relapse and infections after transplantation. (umn.edu)
  • Therefore, inhibition of GSK-3beta could be a strategy for differentiating CD133+ cells into hematopoietic progenitor cells while maintaining their proliferation capacity. (tdl.org)
  • Umbilical cord blood contains a rich and diverse mixture of stem and progenitor cells that have the potential to generate a variety of cell types. (cryo-save.co.za)
  • Epigenetically reprogramming cord blood CD34-positive cells may decrease the high rate of graft failure in adult patients with hematologic cancers. (ascopost.com)
  • The use of umbilical cord blood for hematopoietic stem cell transplantation has been associated with less severe graft-versus-host disease (GVHD) than when the donor is an adult. (medpagetoday.com)
  • ATLANTA -Twelve percent of adults with acute myeloid or acute lymphoblastic leukemia who received umbilical cord blood transplantation experienced graft failure, according to a large European retrospective study presented at the ASH Annual Meeting and Exposition. (healio.com)
  • Our aim was to assess the outcomes of patients with acute leukemia who experience graft failure after umbilical cord blood transplantation," Frederic Baron, MD, PhD, principal investigator at University of Liege in Belgium, said during his presentation. (healio.com)
  • Among the 17 patients receiving a haploidentical transplantation as second graft, 51.8 % (95% CI, 32.4-82.7) achieved 1-year OS and 41.4 % (95% CI, 21.8-78.6) achieved 3-year OS. (healio.com)
  • Even in the mismatched setting, cord blood caused fewer incidences of graft-versus-host disease without losing leukaemia fighting activities. (cryo-save.co.za)
  • Thirty-three patients (61%) achieved sustained engraftment after the second transplantation. (healio.com)
  • CB thaw with albumin-dextran dilution reduces unit manipulation, and minimizes cell loss, speeds time to infusion, is associated with a tolerable infusion reaction profile, and a high rate of sustained engraftment in CBT recipients ≥20 kg. (elsevier.com)
  • Similar to hematopoietic stem cell transplantation (HSCT), disease relapse occurs in unrelated cord blood transplantation (CBT) even the human leukocyte antigen (HLA) alleles are fully matched between donor and recipient. (peerj.com)
  • 2014;49:1400-1404) to associate with transplantation determinants post-HSCT. (peerj.com)
  • In addition to the use of banked cord blood as a source of donor cells for HSCT, cord blood is now emerging as a promising new cell therapy. (cryo-save.co.za)
  • Stem cells from cord blood are successfully used today for the current treatment of serious diseases , such as leukemia, lymphomas, tumors of organs, hereditary and acquired disorders of hematopoiesis (blood formation), the immune system and metabolism, using the transplantation of blood-forming stem cells. (cordbloodcenter.com)
  • Umbilical cord blood from public registers is used especially for treating leukemia in children and adults or genetic disorders of blood formation and metabolism in child patients. (cordbloodcenter.com)
  • After second transplantation, incidence of relapse was 21% at 1 year and 28% at 3 years, nonrelpase mortality was 47% at 1 year and 52% at 3 years, OS was 40% at 1 year and 23% at 2 years, and leukemia-free survival was 33% at 1 year and 21% at 2 years. (healio.com)
  • Main causes of 39 deaths following second transplantation included infection (n = 14) and leukemia relapse/progression (n = 12). (healio.com)
  • He leads the University of Minnesota's Cord Blood Transplantation Program in the treatment of adults and children and is responsible for its international prominence, having first pioneered its use in 1990 in leukemia. (umn.edu)
  • Own cord blood stem cells are also being used in clinical trials for the treatment of cerebral palsy, autism, traumatic brain injury, spinal cord injury, acute burns and more. (cordbloodcenter.com)
  • Allogeneic (donated) cord blood stem cells recently became being used in clinical trials for medicine regenerative applications. (cordbloodcenter.com)
  • Our clinical center for care, noted for exceptional and innovative blood and marrow transplantation, research, and education. (umn.edu)
  • Cryo-Save is championing the first clinical trial to utilise two types of stem cells for the treatment of cerebral palsy. (cryo-save.co.za)
  • The clinical trial aims to demonstrate the safety and preliminary efficacy of sequential intravenous infusion of the ex vivo expanded mesenchymal stem cells (MSC) derived from cord tissue and cord blood stem cells. (cryo-save.co.za)
  • Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. (docphin.com)
  • However, many patients are not able to find an adult stem-cell donor. (ca.gov)
  • Preparation of cord blood (CB) units for infusion by albumin-dextran dilution without centrifugation may be advantageous for adult patients to minimize cell loss and, unlike a bedside thaw, is still conducted in the controlled laboratory environment. (elsevier.com)
  • Since these cells proliferated in culture, they lost expression of adult stem cell markers including CD133, and gained markers of hematopoietic differentiation. (tdl.org)
  • Unipotent cells - occur in the final stage of development and have shown to be capable of differentiating into only one specific adult cell type (e.g. epithelium cells). (famicord.eu)
  • These cells retain the capacity to divide, as opposed to the adult cells. (famicord.eu)
  • Matching cells can be searched in the register of donors of umbilical cord blood. (cordbloodcenter.com)
  • It has been shown that cord blood stem cells are more immunologically tolerant, allowing transplantation without full HLA matching, providing access to transplantation therapies for patients lacking fully matched related or unrelated donors. (cryo-save.co.za)
  • Other sources include the peripheral blood drawn from donors who underwent pharmacological mobilisation. (famicord.eu)
  • Because the protocol developed by Beike allows the use of cord blood stem cells without immune suppression, it can be made available to a wide patient population. (news-medical.net)
  • Compared with the cord blood CD34-positive cells, the valproic acid-treated CD34-positive cells produced a greater number of severe combined immunodeficiency-repopulating cells and established multilineage hematopoiesis in primary and secondary immune-deficient recipient mice. (ascopost.com)
  • These HSCs are primarily responsible for replenishing blood and regenerating the immune system. (cordlifeindia.com)
  • Eventually, these cells perish after a specific period of time, as inscribed in their genetic code. (famicord.eu)
  • A new syndrome characterized by watery diarrhea has been identified in a group of patients who underwent cord blood stem cell transplantation. (medpagetoday.com)
  • Among the 53 patients who underwent a second allogeneic transplantation , the second donor was unrelated (n = 34), HLA haploidentical (n = 17) or an HLA-identical sibling (n = 2). (healio.com)
  • Eight-seven percent of patients underwent reduced-intensity conditioning for the second transplantation. (healio.com)
  • Biology of Blood and Marrow Transplantation , 15 (12), 1596-1602. (elsevier.com)
  • The risks of prolonged antibiotic therapy, including promotion of antimicrobial resistance, must be weighed against the benefits of treating the cord colitis syndrome effectively," they stated. (medpagetoday.com)
  • Hematopoietic stem cell transplantation provides life-saving therapy for thousands of patients each year. (ca.gov)
  • Diseases such as stroke and spinal cord injury, myocardial infarction might possibly be treated with greater efficacy using cord blood stem cell therapy based approaches rather than current treatment options. (cordbloodcenter.com)
  • After the first promising results in the treatment of children with cerebral palsy, in order to extend this therapy, it was considered the possibility of using allogeneic cord blood in adults with ischemic stroke . (cordbloodcenter.com)
  • Committed to providing the highest quality care based on cutting edge research to patients with cancer or non-malignant hematologic diseases such as sickle cell disease. (umn.edu)
  • Dedicated to advancing research on the biological underpinnings of cancer, stem cell biology, sickle cell anemia, endothelial cell biology, and tumor immunology. (umn.edu)
  • The researchers treated dividing cord blood CD34-positive cells ex vivo with several HDAC inhibitors. (ascopost.com)
  • Researchers and faculty explore the science of stem cell biology, respond to the medical needs of today, and educate the researchers of tomorrow. (umn.edu)
  • Our goal is to obtain patentable molecules and processes that can be used to expand stem cells for research and therapeutic uses. (ca.gov)
  • When using cells from a donor, consistency in terms of tissue type (the HLA characteristics) is needed . (cordbloodcenter.com)
  • Cord blood is not just a ''bag of blood stem cells,'' and newer therapies are leveraging the activities of monocytes and other cells in the mix. (cryo-save.co.za)
  • While these results are preliminary, they create hope for cord blood-derived cellular therapies as novel treatments for diseases that cause life-long disabilities and currently have no curative options. (cryo-save.co.za)
  • The cord blood can also be used for research on its stem cells, potentially leading to a greater understanding of, and perhaps therapies for, certain chronic diseases, such as Parkinson's, insulin-dependent diabetes, heart disease, and certain types of cancer. (humanlifeaction.org)
  • Since little is known about signally mechanisms regulating self-renewal and differentiation of UCBSCs, we sought insight from embryonic stem cell (ESC) literature to guide our studies. (tdl.org)
  • However, modern regenerative treatments are increasing beginning to use various types of stem cells that whole cord blood contains. (cordbloodcenter.com)
  • Treating cord blood cells that express CD34 with a combination of histone deacetylase inhibitors and valproic acid increases the number of multipotent cells of functional cord blood stem cells for use as transplantation grafts. (ascopost.com)
  • The umbilical cord is a tube-like structure connecting the foetus to the placenta in mother's womb, providing nutrients and removing waste from baby. (cordlifeindia.com)
  • Cord blood, which is also called "placental blood", is blood that remains in the umbilical cord and placenta following the birth of a baby and after the umbilical cord is cut after delivery. (cordlifeindia.com)
  • Umbilical cord blood stem cells are obtained from the blood contained in the delivered placenta and umbilical cord, which are normally discarded after childbirth. (humanlifeaction.org)
  • However, it also suggests cord-blood-derived stem cells are a safe and viable treatment option for a much broader range of diseases and conditions than previously thought. (news-medical.net)
  • These new findings could open up the use of cord blood for non-hematological diseases, something that to date has not been performed on a wide-spread basis. (news-medical.net)
  • Stem cells hold the promise of treatments and cures for more than 70 major diseases. (umn.edu)
  • To support their data, the European Society for Blood and Marrow Transplantation and EUROCORD sponsored a multicenter retrospective registry study on 1,836 adults with AML or ALL receiving an initial single or double umbilical cord blood transplantation (UCBT) between 2005 and 2016. (healio.com)
  • Stem cell source consisted of single (n = 13) or double (n = 13) umbilical cord blood, peripheral blood stem cells (n = 17), bone marrow (n = 7), or a combination of peripheral blood stem cells plus umbilical cord blood (n = 3) or peripheral blood stem cells plus bone marrow (n = 1). (healio.com)
  • There are only 32 cases of confluent necrotizing hepatitis reported in adults since 1960 and most occur after iatrogenic immunosuppression for bone marrow or solid organ transplantation or in other states of immunosuppression, including acquired immunodeficiency syndrome or chemotherapy treatment. (northwestern.edu)
  • For instance, within the mesoderm, these cells can give rise to bone marrow, blood or muscle cells. (famicord.eu)
  • This means patients will be more likely to find a suitable unrelated cord blood donor than a matched bone marrow donor. (humanlifeaction.org)
  • Cord blood transplantation would complement conventional bone marrow transplantation. (humanlifeaction.org)